323 related articles for article (PubMed ID: 16885367)
1. A novel orally active small molecule potently induces G1 arrest in primary myeloma cells and prevents tumor growth by specific inhibition of cyclin-dependent kinase 4/6.
Baughn LB; Di Liberto M; Wu K; Toogood PL; Louie T; Gottschalk R; Niesvizky R; Cho H; Ely S; Moore MA; Chen-Kiang S
Cancer Res; 2006 Aug; 66(15):7661-7. PubMed ID: 16885367
[TBL] [Abstract][Full Text] [Related]
2. A novel therapeutic combination using PD 0332991 and bortezomib: study in the 5T33MM myeloma model.
Menu E; Garcia J; Huang X; Di Liberto M; Toogood PL; Chen I; Vanderkerken K; Chen-Kiang S
Cancer Res; 2008 Jul; 68(14):5519-23. PubMed ID: 18632601
[TBL] [Abstract][Full Text] [Related]
3. Mutually exclusive cyclin-dependent kinase 4/cyclin D1 and cyclin-dependent kinase 6/cyclin D2 pairing inactivates retinoblastoma protein and promotes cell cycle dysregulation in multiple myeloma.
Ely S; Di Liberto M; Niesvizky R; Baughn LB; Cho HJ; Hatada EN; Knowles DM; Lane J; Chen-Kiang S
Cancer Res; 2005 Dec; 65(24):11345-53. PubMed ID: 16357141
[TBL] [Abstract][Full Text] [Related]
4. CDK4/6 Inhibitor PD 0332991 Sensitizes Acute Myeloid Leukemia to Cytarabine-Mediated Cytotoxicity.
Yang C; Boyson CA; Di Liberto M; Huang X; Hannah J; Dorn DC; Moore MA; Chen-Kiang S; Zhou P
Cancer Res; 2015 May; 75(9):1838-45. PubMed ID: 25744718
[TBL] [Abstract][Full Text] [Related]
5. Prolonged early G(1) arrest by selective CDK4/CDK6 inhibition sensitizes myeloma cells to cytotoxic killing through cell cycle-coupled loss of IRF4.
Huang X; Di Liberto M; Jayabalan D; Liang J; Ely S; Bretz J; Shaffer AL; Louie T; Chen I; Randolph S; Hahn WC; Staudt LM; Niesvizky R; Moore MA; Chen-Kiang S
Blood; 2012 Aug; 120(5):1095-106. PubMed ID: 22718837
[TBL] [Abstract][Full Text] [Related]
6. Expression of p16Ink4a compensates for p18Ink4c loss in cyclin-dependent kinase 4/6-dependent tumors and tissues.
Ramsey MR; Krishnamurthy J; Pei XH; Torrice C; Lin W; Carrasco DR; Ligon KL; Xiong Y; Sharpless NE
Cancer Res; 2007 May; 67(10):4732-41. PubMed ID: 17510401
[TBL] [Abstract][Full Text] [Related]
7. CDK4/6 inhibitor-SHR6390 exerts potent antitumor activity in esophageal squamous cell carcinoma by inhibiting phosphorylated Rb and inducing G1 cell cycle arrest.
Wang J; Li Q; Yuan J; Wang J; Chen Z; Liu Z; Li Z; Lai Y; Gao J; Shen L
J Transl Med; 2017 Jun; 15(1):127. PubMed ID: 28578693
[TBL] [Abstract][Full Text] [Related]
8. Preclinical development of G1T38: A novel, potent and selective inhibitor of cyclin dependent kinases 4/6 for use as an oral antineoplastic in patients with CDK4/6 sensitive tumors.
Bisi JE; Sorrentino JA; Jordan JL; Darr DD; Roberts PJ; Tavares FX; Strum JC
Oncotarget; 2017 Jun; 8(26):42343-42358. PubMed ID: 28418845
[TBL] [Abstract][Full Text] [Related]
9. Pharmacologic inhibition of cyclin-dependent kinase 4/6 activity arrests proliferation in myoblasts and rhabdomyosarcoma-derived cells.
Saab R; Bills JL; Miceli AP; Anderson CM; Khoury JD; Fry DW; Navid F; Houghton PJ; Skapek SX
Mol Cancer Ther; 2006 May; 5(5):1299-308. PubMed ID: 16731763
[TBL] [Abstract][Full Text] [Related]
10. PD-0332991, a potent and selective inhibitor of cyclin-dependent kinase 4/6, demonstrates inhibition of proliferation in renal cell carcinoma at nanomolar concentrations and molecular markers predict for sensitivity.
Logan JE; Mostofizadeh N; Desai AJ; VON Euw E; Conklin D; Konkankit V; Hamidi H; Eckardt M; Anderson L; Chen HW; Ginther C; Taschereau E; Bui PH; Christensen JG; Belldegrun AS; Slamon DJ; Kabbinavar FF
Anticancer Res; 2013 Aug; 33(8):2997-3004. PubMed ID: 23898052
[TBL] [Abstract][Full Text] [Related]
11. Brain Exposure of Two Selective Dual CDK4 and CDK6 Inhibitors and the Antitumor Activity of CDK4 and CDK6 Inhibition in Combination with Temozolomide in an Intracranial Glioblastoma Xenograft.
Raub TJ; Wishart GN; Kulanthaivel P; Staton BA; Ajamie RT; Sawada GA; Gelbert LM; Shannon HE; Sanchez-Martinez C; De Dios A
Drug Metab Dispos; 2015 Sep; 43(9):1360-71. PubMed ID: 26149830
[TBL] [Abstract][Full Text] [Related]
12. Pharmacologic inhibition of CDK4/6: mechanistic evidence for selective activity or acquired resistance in acute myeloid leukemia.
Wang L; Wang J; Blaser BW; Duchemin AM; Kusewitt DF; Liu T; Caligiuri MA; Briesewitz R
Blood; 2007 Sep; 110(6):2075-83. PubMed ID: 17537993
[TBL] [Abstract][Full Text] [Related]
13. Insulin-like growth factor binding protein-3 induces G1 cell cycle arrest with inhibition of cyclin-dependent kinase 2 and 4 in MCF-7 human breast cancer cells.
Kim HS; Lee WJ; Lee SW; Chae HW; Kim DH; Oh Y
Horm Metab Res; 2010 Mar; 42(3):165-72. PubMed ID: 19960406
[TBL] [Abstract][Full Text] [Related]
14. Induction of prolonged early G1 arrest by CDK4/CDK6 inhibition reprograms lymphoma cells for durable PI3Kδ inhibition through PIK3IP1.
Chiron D; Martin P; Di Liberto M; Huang X; Ely S; Lannutti BJ; Leonard JP; Mason CE; Chen-Kiang S
Cell Cycle; 2013 Jun; 12(12):1892-900. PubMed ID: 23676220
[TBL] [Abstract][Full Text] [Related]
15. Selective impact of CDK4/6 suppression on patient-derived models of pancreatic cancer.
Witkiewicz AK; Borja NA; Franco J; Brody JR; Yeo CJ; Mansour J; Choti MA; McCue P; Knudsen ES
Oncotarget; 2015 Jun; 6(18):15788-801. PubMed ID: 26158861
[TBL] [Abstract][Full Text] [Related]
16. Defining the transcriptional and biological response to CDK4/6 inhibition in relation to ER+/HER2- breast cancer.
Knudsen ES; Witkiewicz AK
Oncotarget; 2016 Oct; 7(43):69111-69123. PubMed ID: 27564114
[TBL] [Abstract][Full Text] [Related]
17. Phase 1/2 study of cyclin-dependent kinase (CDK)4/6 inhibitor palbociclib (PD-0332991) with bortezomib and dexamethasone in relapsed/refractory multiple myeloma.
Niesvizky R; Badros AZ; Costa LJ; Ely SA; Singhal SB; Stadtmauer EA; Haideri NA; Yacoub A; Hess G; Lentzsch S; Spicka I; Chanan-Khan AA; Raab MS; Tarantolo S; Vij R; Zonder JA; Huang X; Jayabalan D; Di Liberto M; Huang X; Jiang Y; Kim ST; Randolph S; Chen-Kiang S
Leuk Lymphoma; 2015; 56(12):3320-8. PubMed ID: 25813205
[TBL] [Abstract][Full Text] [Related]
18. Ribociclib, a Cdk4/Cdk6 kinase inhibitor, enhances glucocorticoid sensitivity in B-acute lymphoblastic leukemia (B-All).
Bortolozzi R; Mattiuzzo E; Trentin L; Accordi B; Basso G; Viola G
Biochem Pharmacol; 2018 Jul; 153():230-241. PubMed ID: 29408328
[TBL] [Abstract][Full Text] [Related]
19. CDK4/6 inhibitor palbociclib enhances the effect of pyrotinib in HER2-positive breast cancer.
Zhang K; Hong R; Kaping L; Xu F; Xia W; Qin G; Zheng Q; Lu Q; Zhai Q; Shi Y; Yuan Z; Deng W; Chen M; Wang S
Cancer Lett; 2019 Apr; 447():130-140. PubMed ID: 30677445
[TBL] [Abstract][Full Text] [Related]
20. Monensin-mediated growth inhibition in NCI-H929 myeloma cells via cell cycle arrest and apoptosis.
Park WH; Kim ES; Kim BK; Lee YY
Int J Oncol; 2003 Jul; 23(1):197-204. PubMed ID: 12792794
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]